top of page


Screenshot 2023-03-17 at 2.45.41 PM.png

Acalabrutinib belongs to the class of drugs known as Bruton's tyrosine kinase (BTK) inhibitors. It is used for the treatment of certain types of cancer, specifically mantle cell lymphoma and chronic lymphocytic leukemia.

Acalabrutinib works by blocking the activity of the BTK enzyme, which is involved in the growth and survival of cancer cells. By inhibiting BTK, acalabrutinib can slow down or stop the growth and spread of cancer cells, potentially leading to remission or extended survival.



Screenshot 2023-04-11 at 4.14.23 PM.png
bottom of page